Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Holt

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Thrombosis Research|June 19, 2026
Bleeding risk in patients receiving concurrent treatment with direct oral anticoagulants and corticosteroids: A systematic reviewRosa Talerico, Chiara Cavallaro, Michela Iorio, et al.
International Journal of Cardiology|February 22, 2026
Determinants of changes in peak oxygen consumption in patients with new-onset heart failureMads Hashiba, Mikkel Thunestvedt Hansen, Jørn Wulff Helge, et al.
Annals of Internal Medicine|April 18, 2022
Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover StudyAnders Holt, Paul Blanche, Aksel Karl Georg Jensen, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 4, 2023
High risk of rehospitalization within 1 year following a pulmonary embolism-insights from the Danish nationwide registries from 2000-2020Caroline Sindet-Pedersen, Mohamad El-Chouli, Nina Nouhravesh, et al.
American Heart Journal|November 12, 2022
Prognosis of acute coronary syndrome stratified by cancer type and status - a nationwide cohort studyNina Nouhravesh, Jarl E Strange, Jacob Tønnesen, et al.
The American Journal of Medicine|December 3, 2021
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or DabigatranAnders Holt, Jarl E Strange, Peter Vibe Rasmussen, et al.
Journal of the American College of Cardiology|May 8, 2024
Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in AdultsAnders Holt, Jarl E Strange, Peter Vibe Rasmussen, et al.
European Heart Journal|July 10, 2021
Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control studyJarl Emanuel Strange, Anders Holt, Paul Blanche, et al.
Heart (British Cardiac Society)|August 14, 2021
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulantsAnders Holt, Paul Blanche, Bochra Zareini, et al.
European Heart Journal|June 25, 2020
New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million peopleAnders Holt, Gunnar H Gislason, Morten Schou, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Thrombosis Research|June 19, 2026
Bleeding risk in patients receiving concurrent treatment with direct oral anticoagulants and corticosteroids: A systematic reviewRosa Talerico, Chiara Cavallaro, Michela Iorio, et al.
International Journal of Cardiology|February 22, 2026
Determinants of changes in peak oxygen consumption in patients with new-onset heart failureMads Hashiba, Mikkel Thunestvedt Hansen, Jørn Wulff Helge, et al.
Annals of Internal Medicine|April 18, 2022
Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover StudyAnders Holt, Paul Blanche, Aksel Karl Georg Jensen, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|August 4, 2023
High risk of rehospitalization within 1 year following a pulmonary embolism-insights from the Danish nationwide registries from 2000-2020Caroline Sindet-Pedersen, Mohamad El-Chouli, Nina Nouhravesh, et al.
American Heart Journal|November 12, 2022
Prognosis of acute coronary syndrome stratified by cancer type and status - a nationwide cohort studyNina Nouhravesh, Jarl E Strange, Jacob Tønnesen, et al.
The American Journal of Medicine|December 3, 2021
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or DabigatranAnders Holt, Jarl E Strange, Peter Vibe Rasmussen, et al.
Journal of the American College of Cardiology|May 8, 2024
Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in AdultsAnders Holt, Jarl E Strange, Peter Vibe Rasmussen, et al.
European Heart Journal|July 10, 2021
Oral fluoroquinolones and risk of aortic or mitral regurgitation: a nationwide nested case-control studyJarl Emanuel Strange, Anders Holt, Paul Blanche, et al.
Heart (British Cardiac Society)|August 14, 2021
Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulantsAnders Holt, Paul Blanche, Bochra Zareini, et al.
European Heart Journal|June 25, 2020
New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million peopleAnders Holt, Gunnar H Gislason, Morten Schou, et al.
Pageof 5